(Q35602297)

9 August 2017

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis (English)

1 reference

9 August 2017

1 reference

11

Zsofia Kote-Jarai

1 reference

9 August 2017

Nora Pashayan

1

0 references

Rosalind Eeles

object named as

Rosalind Eeles

series ordinal

13

0 references

Douglas F. Easton

series ordinal

12

object named as

Douglas F Easton

1 reference

9 August 2017

3

Neal DE

1 reference

9 August 2017

14

Pharoah PD

1 reference

9 August 2017

8

Sara Benlloch

1 reference

9 August 2017

10

Mitul Shah

1 reference

9 August 2017

5

Jenny L Donovan

1 reference

9 August 2017

6

Richard M Martin

1 reference

9 August 2017

4

Freddie C Hamdy

1 reference

9 August 2017

9

Ali Amin Al Olama

1 reference

9 August 2017

2

Stephen W Duffy

1 reference

9 August 2017

Patricia Harrington

7

1 reference

PubMed ID

25569441

9 August 2017

language of work or name

English

0 references

publication date

8 January 2015

1 reference

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

10

1 reference

9 August 2017

789-795

1 reference

https://scigraph.springernature.com/pub.10.1038/gim.2014.192

9 August 2017

0 references

cites work

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

The genetic epidemiology of prostate cancer and its clinical implications

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Personalized screening for cancers: should we consider polygenic profiling?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Risk stratification in prostate cancer screening.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Association of prostate cancer risk variants with clinicopathologic characteristics of the disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

25 September 2018

2 references

Crossref

https://api.crossref.org/works/10.1038%2FGIM.2014.192

21 January 2018

12 December 2020

Genetic predisposition to prostate cancer

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FGIM.2014.192

Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4430305

Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease

23 October 2018

1 reference

12 December 2020

Lead-time in the European Randomised Study of Screening for Prostate Cancer

1 reference

12 December 2020

Lead-time in prostate cancer screening (Finland)

1 reference

12 December 2020

Sensitivity in cancer screening

1 reference

12 December 2020

Cumulative association of five genetic variants with prostate cancer

1 reference

12 December 2020

Polygenic susceptibility to breast cancer and implications for prevention

1 reference

12 December 2020

Identifiers

DOI

10.1038/GIM.2014.192

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

PubMed ID

25569441